Cardiovascular disease (CVD) is the cause of over 4.35 million deaths in Europe each year, including nearly half of all nonaccidental deaths, and significantly reduces quality of life. 1 CVD is most often a consequence of atherosclerosis, an inflammation of the arterial blood vessels, which manifests itself in diseases such as coronary artery disease (CAD), congestive heart failure (HF), and cardiac arrhythmias (irregular heart beat). Early detection and prediction of how cardiac diseases progress are key requirements for improved treatment outcomes and a reduction in mortality and morbidity.
observable but play a key role in the pathology of disease, such as measures of pump efficiency and tissue stress, to assist treatment decisions. The most recent international efforts to develop these types of models have been organized in two initiatives: the International Union of Physiological Sciences (IUPS)-sponsored Physiome 10 and the Virtual Physiological Human (VPH) project. 11 Within these frameworks the heart is arguably the most advanced current exemplar of an integrated organ model and represents an excellent organ system to demonstrate the translation of models to clinical application.
Detailed and anatomically finite models of the heart now accurately represent elements of both cardiac anatomy and detailed microstructure (see Figure 1 ). These mathematical descriptions serve as spatial frameworks for embedding functional cellular models of electrical activation, and the resultant tension generation that produces cardiac contraction. These cell and organ components have been combined through the application of continuum equations to simulate whole-organ cardiac electro-mechanics, and coronary and aortic blood flow: see Figure 1 
However, despite advances there remains a significant translational barrier to customizing and applying models for human clinical application. This is because the vast majority of cardiac models are currently developed and validated using data collected from invasive measurements in animal populations under controlled conditions. While these models are useful for proof-of-concept demonstrations of function, the development of mechanistic concepts, and interpretation of specific animal data, there are inherent limitations in the way animal models accurately mimic disease. Moreover, the relevance of insights gained from such animal models to human health remains difficult to determine.
The euHeart project
The current challenge is to quantify and personalize current frameworks for individual patients using extensive but minimally invasive clinical measurements. The goal of integrating and applying this information in patient-specific contexts is the focus of a four-year European Commission project-euHeartwhich will soon be funded as part of the VPH section of the Seventh Framework Programme for research. 12 This project will develop a library of several models of the heart and the great vessels using the established mark-up languages CellML and FieldML. 13, 14 Along with robust and effective personalization strategies, these models will enable the description of normal cardiac and pathological conditions for the major CVDs.
More specifically, models for HF and arrhythmias will incorporate descriptions of ion-channel kinetics into the organlevel solution of reaction-diffusion equations to compute the activation sequences in ventricular and atrial tissue. These applications will also couple the mechanisms for myofilament force generation at the subcellular level to the fluid-mechanical properties of the heart chamber and wall to capture contractile dynamics. Work on CAD will relate perfusion, the delivery of arterial blood to capillaries, to the coronary flow of the whole heart. Mechanical contraction and coronary perfusion will in turn be linked to the constitutive properties of aortic wall tissue to connect heart function and the pressure-flow behavior of the circulation.
This library of models and tools will be integrated into clinical applications to validate the descriptive capabilities of the approach and to demonstrate the plausibility of improving clinical outcomes-when compared to current best practices-for diagnosis, interventional planning, and treatment optimization. Model validation will be carried out on cohorts of patients, and one small-scale multicenter trial, including approximately 120 patients, will be performed to demonstrate the clinical benefit to determine the optimal lead placement in cardiac resynchronization therapy, a treatment that improves the coordination of the heart's contractions.
The long-term outcome of the euHeart program will be a consistent, biophysics-based framework for quantitative data integration, interpretation, and knowledge extraction using the new tools developed. Our hope and expectation is that this will support a paradigm shift away from predefined clinical indices that determine treatment options toward the true personalization of care based on specific individual physiology.
